Jump to content


Fibromuscular dysplasia and hypertension—a statement on behalf of the British and Irish Hypertension Society

BIHS Statement published by the Journal of Human Hypertension November 2020

Measurement of Blood Pressure in the Leg

BIHS Statement published by the Journal of Human Hypertension April 2020

BIHS Statement on ACE/ARB and Covid-19

NICE Hypertension in Adults: Diagnosis and Management (NG136)

BIHS Statement on implementing the new guideline December 2019

Measurement of blood pressure in people with atrial fibrillation

BIHS Statement published by the Journal of Human Hypertension October 2019

The Importance of a Valid Assessment of Salt Intake in Individuals and Populations

BIHS Statement published by the Journal of Human Hypertension April 2019

Oscillometric Measurement of Blood Pressure: A Simplified Explanation

BIHS Technical Note published by the Journal of Human Hypertension April 2019

BIHS Statement on Hydrochlorothiazide and the risk of skin cancer 

BIHS response to recent concerns published by the Journal of Human Hypertension March 2019

BIHS Statement on Diagnosis of Hypertension in Obese Patients November 2017

Guidance on BP monitor cuffs for use in diagnosing hypertension in obese patients.

BIHS Statement on Aspirin October 2017

Response to recent publicity and debate resulting from reports questioning the benefits of aspirin use in those with no history of prior CVD, including those with diabetes, particularly in the context of the known increase in risk of gastrointestinal bleeding.

Population Dietary Salt Reduction and the Risk of Cardiovascular Disease – New Statement, August 2016

In June 2011 the British Hypertension Society, after appraising the quality of publications questioning the appropriateness of population salt reduction, issued a statement supporting the implementation of national and global programmes of moderate reduction in salt intake. The Society now publishes a new statement in light of more recent publications.

The Joint UK Societies 2014 Consensus Statement on Renal Denervation

The Consensus Statement was published in Heart in November 2014.  The above links to the online open-access article.

NICE Clinical Guideline on Atrial Fibrillation

NICE published its Atrial Fibrillation guideline on 18 June 2014.  Please click here to see the BHS response to the recommendations.

The Joint UK Societies Working Group on Renal Denervation
Initial response to the Medtronic Symplicity HTN3 announcement January 2014 

Medtronic announced on January 9th 2014 that a large randomised controlled trial of renal denervation in 530 people with resistant hypertension using the unipolar Symplicity Catheter has not met the primary endpoint for blood pressure reduction.

Sodium in Effervescent, Dispersible and Soluble Medicines Puts Patients at Increased Risk of Cardiovascular Events

Commonly prescribed effervescent, dispersible and soluble medicines containing sodium – used by millions of patients every day – are placing them at a significantly increased risk of cardiovascular events, a new study from the University of Dundee and University College London has shown.

BHS Endorses the Use of Single Pill Combination Treatments in Hypertension August 2013

It is thought that between a third and a half of all medicines prescribed for long-term conditions are not taken as recommended. ‘Simplifying the dosing regimen’ is one way of improving patient adherence as suggested by the NICE medicines adherence guidelines.

Statement on RESPeRATE device April 2012
The BHS has received a number of queries regarding this device since it appeared on the NHS Drug Tariff.  This statement puts forward the BHS view.

Renal Denervation – Joint UK Societies Summary on Renal Denervation
The Joint UK Societies Consensus on Renal Denervation for resistant hypertension

This Joint Societies’ Consensus Statement was prepared to support the National  Institute of Health and Clinical Excellence Interventional Procedure Guidance on  Renal Denervation (NICE IP923) by representatives of key stakeholder societies.

Cochrane Review on salt
The purpose of this statement is to put the findings of the Cochrane Review into the  context of the broader CVD prevention agenda

Dietary Salt Reduction and the Risk of Cardiovascular Disease 
BHS response to a 2011 publication in the Journal of the American Medical  Association reporting that a low salt intake ‘increases’ the risk of CVD.

ARBs and the risk of cancer
BHS response to a 2010 publication in the journal Lancet Oncology which reported  that ARBs may be associated with a modestly increased risk of incident cancer